This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Whatever IT Takes Mentality For Candidates In 2020 Whatever IT Takes Mentality For Medical Device Sales Candidates In 2020 The 2020 theme for candidates trying to break into the medical device sales industry is going to be whatever it takes for more on this let’s break everything down.
After an initial rejection in 2020 and a review delay earlier this year, BioMarin’s Roctavian has finally got the FDA go-ahead to introduce a gene therapy for a not-so-rare disorder.
It was 2020 and Maryland biotech Novavax was thinking big. Novavax purchased the site in May of 2020 for $167 million with the intent of it producing more than 1 billion doses annually there. Novavax purchased the site in May of 2020 for $167 million with the intent of it producing more than 1 billion doses annually there.
Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. | The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics.
Is your team focused on building a reliable tech stack for 2020? Forward thinking sales leaders are starting to prioritize technology initiatives. As organizations chase new revenue targets, B2B sales leaders must examine cutting edge prospecting solutions that proactively help reps identify, connect with, and close qualified buyers faster.
It’s also the first medicine using the revolutionary CRISPR gene-editing system, which earned its inventors a Nobel Prize in 2020 and holds tantalizing potential to cure diseases for which there is no treatment.
Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit, the company confirmed Friday. Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker.
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. That changed Friday.
The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. | The following year, the agency doled out a complete response letter, dashing Supernus' second try.
This report aims to highlight the current state of B2B database and contact acquisition strategies and organizations’ goals to leverage data to fuel their go-to-market strategies in 2020 and beyond.
From 2016 to 2020, the 14 leading drug companies spent $577 billion on stock buybacks and dividends—$56 billion more than they spent on R&D over the same period.” ” From 2016 to 2020, compensation for the 14 companies’ top executives totaled $3.2 The drug industry is driven by profits, not by patient’s needs.
It’s been 15 years since Genzyme began rationing the Fabry disease treatment Fabrazyme after a shortage caused by contamination at a manufacturing site, marking the start of many years of litigatio | Sanofi's Genzyme was accused of causing injuries after contaminated doses of its Fabry disease drug led to a shortage, during which the company rationed (..)
According to data from KFF’s annual survey of employers , between 2010 and 2020, insurance premiums for employer-sponsored family coverage rose by 55 percent; the employer’s contribution went up 61 percent. On a percentage basis, the figure for 2020 was Independence’s highest profit margin since 2011, records show.
The loss of patent protection on Amarin’s sole commercial product Vascepa in 2020 has led to a roller coaster ride for the Dublin-based company over the past few years. Amarin is getting a fresh shot to challenge Hikma Pharmaceuticals’ generic version of its fish oil-derived heart med in the lower courts. business.
Discover valuable insights and practical steps on how to: Adjust your tactics to deal with the impact of 2020. If your role includes supporting sellers, then this in-depth sales enablement guide is for you! Keep remote onboarding and training engaging (including SKO). Deliver content and tools sellers will love.
The 2020-approved breast cancer med booked $17.9 MacroGenics’ first commercial product, breast cancer drug Margenza, is heading off to TerSera Therapeutics through a $40 million hand-off. | million in 2023 sales as it struggled to make a mark in the crowded market.
< | The deal with the Israel Tax Authority wraps up pending litigation over taxes payable from 2008 to 2020. With an agreement to make payments totaling $750 million over the next five years, Teva can wipe its slate clean of litigation from Israeli regulators that concerns over a decade's worth of taxes.<
In 2020, Palatin Technologies paid $12 million to regain the rights in North America to its struggling female libido drug Vyleesi. | In 2020, Palatin paid $12 million to regain the rights in North America to its struggling female libido drug Vyleesi.
GSK’s Cabenuva made history in 2020 as the world’s firs | GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative.
After admitting to the crime four years ago, a former Sandoz executive will avoid hard time for his part in a generic drug price-fixing scheme. | Hector Kellum agreed to cooperate with federal investigators in 2020, admitting his part in a massive generics price-fixing scheme that spanned many companies.
2020 trend concept. Hand flip wood cube change year 2019 to 2020. In my opinion, this is due to pharma being sold on programmatic and the lack of investment in creative. 9ine: Searches for specific medical terms have increased, indicating that people don’t necessarily understand common medical terms.
The Securities and Exchange Commission (SEC) has revealed insider trading charges against five—including former Alexion Vice President | The SEC has revealed insider trading charges against five—including former Alexion vice president Joseph Dupont and a Massachusetts police chief—who allegedly took advantage of prior knowledge of Alexion’s 2020 acquisition (..)
billion in 2020 to a projec | A phase 3 study has shown that a new, subcutaneous version of Roche's Ocrevus has proven to be non-inferior to the current infused treatment as measured by the level of drug in the blood, 12 weeks after administration. With the multiple sclerosis market growing rapidly—from $18.9
According to a new report , life expectancy in the United States took another hit in 2021, furthering a dramatic decline from 2020 that was the largest since World War II. years in 2020 and 76.60 In contrast, peer countries averaged a smaller decrease in life expectancy between 2019 and 2020 (0.57 years in 2019 to 76.99
billion in 2020 (2020 U.S. Newly approved cancer drugs cost an average of $10,000 per month, with some as high as $30,000 per month. Just over a decade ago, the standard was $4,500. National costs for cancer care were estimated to be $190.2 billion in 2015 and $208.9 population.
According to the Lancet, a medical journal, the incidence of depression and anxiety has soared in the pandemic—by more than 25% globally in 2020. In October 2020, hackers who had breached Vastaamo, a famous Finnish startup, began blackmailing its users. But are they safe and effective?
Now, the manufacturing arriviste—which was founded in 2020—is expanding its production network again with the acquisition of Switzerland's Baccinex, which specializes in fill and finish services.
Incyte previously bought into a Monjuvi collaboration for $750 million ahead of the drug's 2020 approval. . | While Incyte gained more rights to lymphoma med Monjuvi, Novartis claimed the rest of MorphoSys for €2.7B
A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3 2020 was a massive year for biotech venture financing – and 2021 has already eclipsed it. VCs prefer to fund companies that already seemed like a sure bet – in other words, were far along.
By the look of 2020’s results, he’s on the right track—and his compensation shows it. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6 million, the company disclosed in a proxy filing” No biosimilar will take on Humira’s $16 billion in 2020 U.S.
After triumphing over Novartis’ Cosentyx in a 2020 psoriasis study, Skyrizi has dished out another serving of competitor-busting data. AbbVie's Skyrizi has dished out another serving of competitor-busting data, this time going head-to-head against Amgen’s Otezla.
Under a 2020 collaboration with MyoKardia, LianBio has held Asian rights to the potential blockbuster cardio drug mavacamten. LianBio originally held the med's Asia commercialization rights under a 2020 collaboration with MyoKardia, which was later bought by Bristol Myers. Now, BMS is ponying up for those rights.
Two novel events drove the 2020 data: the inclusion of Early Access content in the JCR for the first time, and the sudden appearance of COVID-19 as an entirely new, extremely urgent field of study. These factors made the 2020 data explored in last year’s release particularly unusual.
Hopes around FibroGen’s anemia drug roxadustat were high in early 2020 when Enrique Conterno arrived as the company’s new CEO. Enrique Conterno has resigned from the FibroGen CEO post for “personal reasons,” the company said Tuesday.
Aggregate visit volumes for telehealth and in-person Primary Care visits in October 2020 were 7% lower than the volume of solely in-person Primary Care visits for October 2019. Before and after the onset of the COVID-19 pandemic, Behavioral Health accounted for the most significant share of telehealth visits. On average, in 2021, 57.9%
Back in 2020, a surprise manufacturing shortfall led to an import ban of Bristol Myers Squibb’s Abraxane, sold by BeiGene, in China. Back in 2020, a surprise manufacturing shortfall led to an import ban of Bristol Myers Squibb’s Abraxane, sold by BeiGene, in China.
What Candidates Can Learn From Kobe Bryant’s Mentality For Sales Interviews Hey welcome back you guys everyone’s having an awesome work week, so far I hope everyone is having a great start to 2020 I hope everyone’s got that 2020 vision locked in remember.
prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 Using pricing data from 2019 and 2020, ICER pegged Humira’s net price increase at 9.6% According to Reuters “drugmakers hiked U.S. billion, a U.S. group that reviews the value of medicines said on Tuesday.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content